A study led by Guadalupe Sabio and José Jalife at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) in Madrid has identified a new signaling mechanism implicated in the development of ventricular fibrillation, a type of arrhythmia, or irregular heartbeat.
FDA Greenlights Imaging Agent to Detect Residual Cancer After Lumpectomy
The FDA approved pegulicianine (LumiSight) as an optical imaging agent for detecting residual cancer after breast-conserving surgery (BCS). The approval stipulates use of pegulicianine with
April 19, 2024